Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1024 - A China-Manufactured Bevacizumab Biosimilar, HLX04, Matches Avastin® Sourced from China, USA and European Union

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

YanHua Ding

Citation

Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431

Authors

Y. Ding1, T. Yu2, J. Sun3, M. Wu1, Q. Chen2, H. Qian2, L. Xie2, X. Zhang4, E. Liu4, W. Jiang5, S. Liu5, A. LUK4

Author affiliations

  • 1 Phase I Clinical Trials Unit, The First Hospital of Jilin University, 130000 - Changchun/CN
  • 2 Phase I Clinical Trials Unit, Shanghai Xuhui Central Hospital, Shanghai/CN
  • 3 Phase I Clinical Trials Unit, The First Hospital of Jilin University, Changchun/CN
  • 4 Global Clinical And Medical Affairs, Shanghai Henlius Biopharm, 200233 - Shanghai/CN
  • 5 Executive Office, Shanghai Henlius Biopharm, 200233 - Shanghai/CN
More

Resources

Abstract 1024

Background

Barriers to becacizumab (Avastin®) access involved not only treatment costs but lack of treatment guidelines and drug supplies across the USA, Europe and emergent market. The limit access to treatment resulted in reducing the number of planned bevacizumab cycle treatments with impact on patient quality-of-life and survival. HLX04, a proposed bevacizumab biosimilar, is required to demonstrate pharmacokinetics (PK) and safety bioequivalence in compared with reference product, attempting to address unmet medical needs in which bevacizumab is frequently used in metastatic colorectal cancer (mCRC).

Methods

We completed a PK, safety and immunogenicity equivalence study evaluating HLX04 and Avastin® sourced from US, the European Union (EU), and China (CN).The primary PK endpoints were serum area-under-the concentration time curves AUC0-∞ and AUC0-tau. Other endpoints included Cmax, safety and immunogenicity. The equivalence was achieved if 90% confidence intervals (CIs) for the test-to-reference ratios of PK parameters were within the 80-125% equivalence margin ranges by pairwise comparisons. Subsequently, we initiated a multi-center, randomized, double-blind, parallel-controlled, phase 3 study (HLX04-mCRC03) comparing the efficacy, safety and immunogenicity profiles of HLX04 or Avastin® with oxaliplatin and fluorouracil-based chemotherapy (XELOX or mFOLFOX6) regimen for the first-line treatment of mCRC. The primary efficacy endpoint was progression free survival rate up to month 9 (PFSR9m); safety endpoints included immunogenicity and adverse events.

Results

Based on a total of 208 healthy males being randomized at 1:1:1:1 ratio to each study arm (HLX04 and bevacizumab sourced from US, EU or CN at 3 mg/kg) and were followed up uo 99 days, a four-way PK equivalence among HLX04 and all three reference products (Table) was established. Adverse drug reactions (ADRs) were noted in 153 (76.1%) subjects: 42 (82.4%), 38 (74.5%), 39 (75.0%) and 34 (72.3%) from the HLX04 and bevacizumab sourced from US, EU and CN arms, respectively. The most common ADR was elevated transaminases (n = 38 [18.9%]). One subject from EU arm suffered from a grade 4 non-drug-related AE (hypertriglyceridemia). No grade 5 AEs were reported. No anti-drug antibodies were detected in all arms. Based on these results, approximately 640 patients with mCRC will be randomized in 60 centers at 1:1 ratio to receive either HLX04 or Avastin® in an ongoing phase 3 pivotal study.Table: 105P

Statistical comparison of key PK parameters

ParametersPairRatio(%)90% CI
AUC0-∞ (μg·h/mL)HLX04 vs bevacizumab-CN bevacizumab-CN vs bevacizumab-EU HLX04 vs bevacizumab-EU HLX04 vs bevacizumab-US bevacizumab-US vs bevacizumab-EU95.4 100.5 95.9 99.0 96.990.6, 100.5 95.1,106.3 91.3,100.9 93.5,104.9 91.2,102.9
AUC0-t (μg·h/mL)HLX04 vs bevacizumab-CN bevacizumab-CN vs bevacizumab-EU HLX04 vs bevacizumab-EU HLX04 vs bevacizumab-US bevacizumab-US vs bevacizumab-EU95.9 100.3 96.2 99.4 96.891.2,100.9 95.1, 105.9 91.7, 101.0 94.0, 105.0 91.4, 102.7
Cmax (ng/mL)HLX04 vs bevacizumab-CN bevacizumab-CN vs bevacizumab-EU HLX04 vs bevacizumab-EU HLX04 vs bevacizumab-US bevacizumab-US vs bevacizumab-EU104.1 98.1 102.2 105.4 97.099.8, 108.6 94.0, 102.4 98.1, 106.5 101.0, 109.8 93.0, 101.1

Conclusions

The four-way PK and safety equivalence of HLX04 and bevacizumab sourced from US, EU and China were established. To the best of our knowledge, we are first reporting the 4-way PK equivalence among HLX04, a proposed bevacizumab biosimilar, and three differently sourced Avastin®.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Shanghai Henlius Biotech, Inc.

Funding

Shanghai Henlius Biotech, Inc.

Disclosure

X. Zhang, A. Luk: Employment: Shanghai Henlius Biotech, Inc. E. Liu: Employment: Henlix Biotech, Inc. W. Jiang, S. Liu: Employment: Shanghai Henlius Biotech, Inc.; Stock ownership of Shanghai Henlius, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.